Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | BRD2 | P25440 | 19/20 | 1.00 |
| ▸ | BRD3 | Q15059 | 19/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17646147 | 0.88 | BRD4 (1.00) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL17646141 | 0.87 | BRD4 (1.00) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL17660068 | 0.87 | BRD2 (0.77) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL17646155 | 0.87 | BRD2 (0.77) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL18092455 | 0.84 | BRD4 (1.00) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL17646137 | 0.84 | BRD4 (1.00) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL16244910 | 0.83 | BRD4 (1.00) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL17646135 | 0.82 | BRD4 (1.00) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL17646152 | 0.81 | BRD4 (1.00) | BRD4BRD2BRD3CREBBP | |
| SCHEMBL17646136 | 0.81 | BRD4 (1.00) | BRD4BRD2BRD3CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004112-B1 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-08-30 | — | — | EP | claimed |
| US-9714249-B2 | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2017-07-25 | — | — | US | claimed |
| US-20160096843-A1 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-07 | — | — | US | claimed |
| EP-3004112-B1 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-08-30 | — | — | EP | disclosed |
| US-9714249-B2 | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2017-07-25 | — | — | US | disclosed |
| US-9714249-B2 | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2017-07-25 | — | — | US | disclosed |
| US-9714249-B2 | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2017-07-25 | — | — | US | disclosed |
| US-20160096843-A1 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-07 | — | — | US | disclosed |
| US-20160096843-A1 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-07 | — | — | US | disclosed |
| US-20160096843-A1 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096843-A1 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BET1, BRD4, PHKB | BRD4 2/4885BRD2 13/4885BRD3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.